Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX open-label extension of AMX0035 in adults with amyotrophic lateral sclerosis
NL-OMON53858Phase 3Completed
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sodium phenylbutyrate in amyotrophic lateral sclerosis (ALS), sponsored by Amylyx Pharmaceuticals. Primary endpoint: Long-term safety and tolerability. Started Jan 2023; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON53858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53858.